Drug Trial Radar · NCT02230566
A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)
Last checked: Nov 20, 2026Latest source record: Jul 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
Dec 2014
Primary completion
May 2016
Study completion May 2016
Sponsor
- Lead sponsor
- Ultragenyx Pharmaceutical IncIndustry
- Sponsor type
- Industry
- First posted
- Sep 3, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 5 years, up to 35 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Phase 3 study will use a novel randomized, intra-subject placebo-controlled, single crossover design, referred to as Blind Start, to evaluate the safety and efficacy of UX003. The Blind Start is a novel design whereby participants will be randomized to 1 of 4 groups, each representing a different treatment sequence, and will cross over to UX003 at different pre-defined time points in a blinded manner. All groups will receive a minimum of 24 weeks treatment with 4 mg/kg UX003 every other week (QOW).
Conditions
- MPS 7
- Sly Syndrome
- Mucopolysaccharidosis
- MPS VII
Interventions
UX003Drug
UX003 is a sterile concentrate formulation of rhGUS for intravenous infusion
PlaceboOther
Placebo consisting of the UX003 formulation buffer (without rhGUS)
Primary outcomes
What the sponsor says the trial is designed to measure.
- European Union (EU) and Rest of World: Percentage Change From Baseline in Urinary Glycosaminoglycan (uGAG) Dermatan Sulfate (DS) at UX003 Treatment Week 24Time frame: Baseline (defined as the average of all assessments prior to or on the date of cross-over to active treatment with UX003) to 24 weeks of UX003 study drug treatment
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Children's Hospital Oakland
Oakland, California
Children's Hospital of Orange County
Orange, California
Miami Children's Hospital
Miami, Florida
University of Minnesota
Minneapolis, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.